Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis
Brain · 2023
DOI: 10.1093/brain/awac306 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Brain, 2023. Verfasst von Daisuke Ito und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Induced Pluripotent Stem Cells, Neurodegenerative Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology of Japan, Foundation of Japan Amyotrophic Lateral Sclerosis Association, the Ice Bucket Challenge Grant, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Using patient-derived induced pluripotent stem cells, neurodegenerative disease phenotypes have been recapitulated and their pathogenesis analysed leading to significant progress in drug screening. In amyotrophic lateral sclerosis, high-throughput screening using induced pluripotent stem cells-derived motor neurons has identified candidate drugs. Owing to induced pluripotent stem cell-based drug evaluation/screening, three compounds, retigabine, ropinirole and bosutinib, have progressed to clinical trials. Retigabine blocks hyperexcitability and improves survival in amyotrophic lateral sclerosis patient-derived motor neurons. In a randomized clinical trial (n = 65), treatment with retigabine reduced neuronal excitability after 8 weeks. Ropinirole, identified in a high-throughput screening, attenuates pathological phenotypes in patient-derived motor neurons. In a trial limited by a small sample size (n = 20), ropinirole was tolerable and had clinical benefits on function and survival. A phase 1 study of bosutinib has reported safety and tolerability for 12 weeks. Thus, these clinical trials show safety and positive effects and confirm the reliability of stem cell-based drug discovery. This novel strategy leads to reduced costs and time when compared to animal testing and opens new avenues for therapy in intractable diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Neurology, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Neurology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan.
ORCID-Profile: Daisuke Ito
Förderung
- Ministry of Education, Culture, Sports, Science and Technology of Japan
- Foundation of Japan Amyotrophic Lateral Sclerosis Association, the Ice Bucket Challenge Grant
- Japan Agency for Medical Research and Development
- AMED
Zitieren
APA
Ito, D., Morimoto, S., Takahashi, S., Okada, K., Nakahara, J., & Okano, H. (2023). Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis. Brain. https://doi.org/10.1093/brain/awac306
Vancouver
Ito D, Morimoto S, Takahashi S, Okada K, Nakahara J, Okano H. Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis. Brain. 2023. doi:10.1093/brain/awac306
BibTeX
@article{Ito2023,
author = {Ito, Daisuke and Morimoto, Satoru and Takahashi, Shinichi and Okada, Kensuke and Nakahara, Jin and Okano, Hideyuki},
title = {Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awac306}
}
EUVIMED